Cargando…

Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors

The botulinum neurotoxin type D is one of seven highly potent toxins produced by Clostridium botulinum which inhibit neurotransmission at cholinergic nerve terminals. A functional fragment derived from the toxin, LHn, consisting of the catalytic and translocation domains, has been heralded as a plat...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuyer, Geoffrey, Davies, Jonathan R., Moore, Kevin, Chaddock, John A., Ravi Acharya, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555039/
https://www.ncbi.nlm.nih.gov/pubmed/26324071
http://dx.doi.org/10.1038/srep13397
_version_ 1782388120499519488
author Masuyer, Geoffrey
Davies, Jonathan R.
Moore, Kevin
Chaddock, John A.
Ravi Acharya, K.
author_facet Masuyer, Geoffrey
Davies, Jonathan R.
Moore, Kevin
Chaddock, John A.
Ravi Acharya, K.
author_sort Masuyer, Geoffrey
collection PubMed
description The botulinum neurotoxin type D is one of seven highly potent toxins produced by Clostridium botulinum which inhibit neurotransmission at cholinergic nerve terminals. A functional fragment derived from the toxin, LHn, consisting of the catalytic and translocation domains, has been heralded as a platform for the development of targeted secretion inhibitors. These secretion inhibitors are aimed at retargeting the toxin towards a specific cell type to inhibit vesicular secretion. Here we report crystal structures of LHn from serotype D at 2.3 Å, and that of SXN101959 at 3.1 Å resolution. SXN101959, a derivative that combines LHn from serotype D with a fragment of the growth hormone releasing hormone, has previously revealed promising results in inhibiting growth hormone release in pituitary somatotrophs. These structures offer for the first time insights into the translocation domain interaction with the catalytic domain in serotype D. Furthermore, structural information from small-angle X-ray scattering of LHn/D is compared among serotypes A, B, and D. Taken together, these results demonstrate the robustness of the ‘LHn fold’ across serotypes and its use in engineering additional polypeptide components with added functionality. Our study demonstrates the suitability of botulinum neurotoxin, and serotype D in particular, as a basis for engineering novel secretion inhibitors.
format Online
Article
Text
id pubmed-4555039
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-45550392015-09-11 Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors Masuyer, Geoffrey Davies, Jonathan R. Moore, Kevin Chaddock, John A. Ravi Acharya, K. Sci Rep Article The botulinum neurotoxin type D is one of seven highly potent toxins produced by Clostridium botulinum which inhibit neurotransmission at cholinergic nerve terminals. A functional fragment derived from the toxin, LHn, consisting of the catalytic and translocation domains, has been heralded as a platform for the development of targeted secretion inhibitors. These secretion inhibitors are aimed at retargeting the toxin towards a specific cell type to inhibit vesicular secretion. Here we report crystal structures of LHn from serotype D at 2.3 Å, and that of SXN101959 at 3.1 Å resolution. SXN101959, a derivative that combines LHn from serotype D with a fragment of the growth hormone releasing hormone, has previously revealed promising results in inhibiting growth hormone release in pituitary somatotrophs. These structures offer for the first time insights into the translocation domain interaction with the catalytic domain in serotype D. Furthermore, structural information from small-angle X-ray scattering of LHn/D is compared among serotypes A, B, and D. Taken together, these results demonstrate the robustness of the ‘LHn fold’ across serotypes and its use in engineering additional polypeptide components with added functionality. Our study demonstrates the suitability of botulinum neurotoxin, and serotype D in particular, as a basis for engineering novel secretion inhibitors. Nature Publishing Group 2015-09-01 /pmc/articles/PMC4555039/ /pubmed/26324071 http://dx.doi.org/10.1038/srep13397 Text en Copyright © 2015, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Masuyer, Geoffrey
Davies, Jonathan R.
Moore, Kevin
Chaddock, John A.
Ravi Acharya, K.
Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors
title Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors
title_full Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors
title_fullStr Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors
title_full_unstemmed Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors
title_short Structural analysis of Clostridium botulinum neurotoxin type D as a platform for the development of targeted secretion inhibitors
title_sort structural analysis of clostridium botulinum neurotoxin type d as a platform for the development of targeted secretion inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555039/
https://www.ncbi.nlm.nih.gov/pubmed/26324071
http://dx.doi.org/10.1038/srep13397
work_keys_str_mv AT masuyergeoffrey structuralanalysisofclostridiumbotulinumneurotoxintypedasaplatformforthedevelopmentoftargetedsecretioninhibitors
AT daviesjonathanr structuralanalysisofclostridiumbotulinumneurotoxintypedasaplatformforthedevelopmentoftargetedsecretioninhibitors
AT moorekevin structuralanalysisofclostridiumbotulinumneurotoxintypedasaplatformforthedevelopmentoftargetedsecretioninhibitors
AT chaddockjohna structuralanalysisofclostridiumbotulinumneurotoxintypedasaplatformforthedevelopmentoftargetedsecretioninhibitors
AT raviacharyak structuralanalysisofclostridiumbotulinumneurotoxintypedasaplatformforthedevelopmentoftargetedsecretioninhibitors